Physician profile
Bradley D Wasson
NPI 1386604825
$733,695.17
in general payments reported to CMS, 2019-2025
34 companies · $146K in 2025
The $146K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $29K · 2021: $123K · 2022: $132K · 2023: $140K · 2024: $152K · 2025: $146K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $329K · Travel and Lodging: $83K · Consulting Fee: $14K · Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $328,510.00 |
| Travel and Lodging | $82,834.28 |
| Consulting Fee | $14,065.00 |
| Food and Beverage | $12,547.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $633,538.65 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $67,783.60 | 2019-2025 | Capvaxive, Vaxneuvance, Gardasil 9 |
| Pfizer INC. | $19,028.75 | 2022-2025 | |
| Sanofi Pasteur INC. | $9,601.51 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $1,200.00 | 2021 | |
| Novo Nordisk INC | $342.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $285.73 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $265.24 | 2022-2024 | Jardiance, Mounjaro, Emgality |
| Abbott Laboratories | $248.59 | 2019-2025 | Freestyle Libre |
| Abbvie INC. | $221.88 | 2021-2025 | Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.48 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $152.05 | 2019-2025 | Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $134.97 | 2023-2024 | |
| Exact Sciences Corporation | $87.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dynavax Technologies Corporation | $72.79 | 2023-2025 | Heplisav-B |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $60.13 | 2019-2020 | |
| Astellas Pharma US INC | $46.65 | 2019-2024 | Veozah |
| Supernus Pharmaceuticals, INC. | $43.35 | 2019-2022 | |
| Allergan, INC. | $35.45 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $34.70 | 2022 | |
| Idorsia Pharmaceuticals US INC | $33.19 | 2023 | Quviviq |
| Radius Health, INC. | $32.37 | 2022 | |
| Dexcom, INC. | $32.12 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $30.04 | 2019 | |
| Seqirus USA INC | $27.96 | 2025 | Flucelvax, Fluad |
| Insulet Corporation | $25.33 | 2022-2023 | Omnipod |
| Janssen Pharmaceuticals, INC | $24.21 | 2019 | |
| Genentech USA, INC. | $23.97 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $23.77 | 2024 | |
| Esperion Therapeutics, INC. | $18.33 | 2025 | Nexletol |
| Amarin Pharma, INC. | $16.99 | 2020 | |
| Shire North American Group INC | $12.90 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.83 | 2023 | Xifaxan, Trulance |
| Ironwood Pharmaceuticals, INC | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Wasson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.